Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study
- 11 January 2016
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 36 (3) , 235-242
Abstract
Body-image issues associated with dermatological side effects induced by anticancer-targeted therapies have not been specifically explored until now despite growing literature about their impact on quality of life. Prospective and longitudinal investigations were needed. The aim of our study was to describe body-image changes occurring with cutaneous toxicities and their psychosocial impact on patients. Thirty-three patients were evaluated four times during the first 3 months of targeted therapy in terms of body satisfaction, physical attitudes and depression with validated and ad hoc questionnaires. The NCI-CTCAE V4.0 was used to grade adverse dermatological events. Descriptive and inferential analyses were conducted with SPSS 14.0 software. Ninety-four per cent of the patients developed skin toxicities. Body satisfaction remained stable and slightly better than average over this period. About one-third of the patients reported body-image issues at baseline. Body satisfaction and depression levels at baseline appeared to be significantly associated with body-image issues after 3 months of therapy. In the framework of regular dermatological monitoring, skin toxicities did not appear to be associated with body-image issues. Body satisfaction and depressive symptoms at the beginning of targeted therapy emerged as critical factors that practitioners should consider in order to prevent deterioration of body image that could impact on quality of life and compromise compliance.Keywords
This publication has 22 references indexed in Scilit:
- The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trialsTargeted Oncology, 2013
- The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)Supportive Care in Cancer, 2012
- The impact of dermatological toxicities of anti‐cancer therapy on the dermatological quality of life of cancer patientsJournal of the European Academy of Dermatology and Venereology, 2012
- HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot SyndromeThe Oncologist, 2011
- The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesJournal of the American Academy of Dermatology, 2011
- Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional studyHealth and Quality of Life Outcomes, 2010
- Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patientsSupportive Care in Cancer, 2009
- Effets cutanés des nouvelles molécules utilisées en cancérologieLa Revue de Médecine Interne, 2009
- Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l’EGFAnnales de Dermatologie et de Vénéréologie, 2008
- The family impact of skin diseases: the Greater Patient conceptBritish Journal of Dermatology, 2007